Answers are grounded in this paper and cite their sources.
Shows thrombomodulin-impairing mutations occur in approximately 5% of patients with atypical hemolytic-uremic syndrome, indicating an underlying genetic mechanism.
Mutations that impair the function of thrombomodulin occur in about 5% of patients with atypical hemolytic-uremic syndrome.
No takes yet. Share an insight, caveat, or question.
Delvaeye et al. (2009) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: